New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
21:13 EDTTSROTESARO announces final results from three Phase 3 trials of rolapitant
TESARO announced that final results from three Phase 3 trials of rolapitant, an investigational neurokinin-1 receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting, were presented at the American Society of Clinical Oncology, ASCO, annual meeting in Chicago. "We are very pleased with these pivotal data which, along with the previously conducted Phase 2 study, will form the basis of our New Drug Application submission to the U.S. Food and Drug Administration in mid-2014," said Mary Lynne Hedley, Ph.D., president of TESARO. "Additionally, we look forward to expanding our niraparib development program to include clinical trials in the small cell lung cancer and first line ovarian cancer settings."
News For TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
07:02 EDTTSROTESARO 3.4M share Secondary priced at $51.00
Subscribe for More Information
March 2, 2015
16:22 EDTTSROTESARO files to sell $150M of common stock
Subscribe for More Information
February 23, 2015
06:25 EDTTSROMedivation removed from Focus List at Citigroup
Subscribe for More Information
06:23 EDTTSROCiti ups TESARO price target to $79, adds to focus list
Subscribe for More Information
February 20, 2015
05:53 EDTTSROTESARO price target raised to $50 from $44 at Mizuho
Mizuho raised its price target for TESARO shares to $50 citing increased confidence and market opportunity for niraparib following the company's Q4 results. The firm expects approval for rolapitant in Q3 and reiterates a Buy rating on the stock.
February 19, 2015
16:13 EDTTSROTESARO reports Q4 EPS ($1.33), consensus ($1.03)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use